J.P.Morgan downgrades India equities to 'neutral' on oil-led earnings risks, higher valuations

By Bharath Rajeswaran
April 24 (Reuters) - J.P.Morgan downgraded Indian equities to "neutral" from "overweight," citing elevated valuations compared to emerging market peers and pressure on earnings from energy supply shocks linked to the Iran war, a day after HSBC lowered its rating.
Surging crude prices could stoke inflation and growth risks for the country, squeeze consumption and weigh on near-term corporate margins, with a weakening rupee adding to the pressure, the brokerage said in a note on Friday.
Earlier this month, J.P.Morgan cut FY2027 earnings estimates by 2%-10% across domestic sectors such as energy, consumer, auto and financials. It also reduced MSCI India earnings growth forecasts for 2026 and 2027 by 2 percentage points and 1 percentage point, respectively, to 11% and 13%.
Additionally, the brokerage lowered its year-end target for the benchmark Nifty 50 by 10% to 27,000. The Nifty .NSEI and Sensex .BSESN have fallen 8.5% and 10% this year and are currently trading about 9.3% and 11% lower than record highs hit in early 2026 and late 2025, respectively.
"Despite the recent drop, India still trades at a significant premium to peers like Korea, Brazil, China, Mexico and South Africa, which all offer an inexpensive entry point for higher or similar forward earnings growth," said J.P.Morgan.
India also lacks meaningful exposure to high-growth themes such as AI, data centers, robotics, and semiconductors, which could limit earnings growth compared to emerging market peers with a stronger presence in these segments, the brokerage added.
The Wall Street firm flagged market dilution as another growing challenge. Although strong local inflows have cushioned foreign selling, stake sales by top shareholders and record issuance through IPOs and QIPs are limiting equity market gains.
While J.P.Morgan said the country's long-term growth story is still intact, the near-term outlook has weakened.
It remains "overweight" on sectors including financials, materials, consumer discretionary, hospitals, defense, and power, while staying "underweight" on IT and pharmaceuticals.
The above content was completed with the assistance of AI and has been reviewed by an editor.
Disclaimer: The content available on Mitrade Insights is provided for informational and marketing purposes only. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.
Nothing in this material constitutes investment advice, personal recommendation, investment research, an offer, or a solicitation to buy or sell any financial instrument. The content has been prepared without consideration of your individual investment objectives, financial situation, or needs, and should not be treated as such.
Past performance is not a reliable indicator of future performance and/or results. Forward-looking scenarios or forecasts are not a guarantee of future performance. Actual results may differ materially from those anticipated.
Mitrade makes no representation or warranty as to the accuracy or completeness of the information provided and accepts no liability for any loss arising from reliance on such information.




